ArticleInfectious diseases and therapy2018

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials.

Tram T Tran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.